Brain Injury Traumatic SevereMOSS-THINKNCT05778110
Multiomic Analysis of Traumatic Brain Injury and Hypertension Intracranial Hemorrhage Lesion Tissue
An observational study of Brain Injury Traumatic Severe and Intracranial Hemorrhage, Hypertensive, run by RenJi Hospital at 1 site in China.
Trial summary
The goal of this experimental observation study is to figure out differently expressed biomarkers in lesion tissues in traumatic brain injury or hypertension intracranial hemorrhage patients. Read more about this study
- Who is it for?
- Ages 16 to 65 years
- Conditions the study is for
- Brain Injury Traumatic Severe, Intracranial Hemorrhage, Hypertensive
- What is being tested?
- Type of disease
- How many people
- 10 participants
- Where
- 1 siteChina
- Study dates
- 1 Apr 2023to 31 Dec 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 to 65 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients with severe traumatic brain injury or hypertensive intracranial hemorrhage.
Who may be able to join
- Age >18 and <65
- Within 12 hours after brain injury
- GCS ≥3 and ≤8
- Closed brain injury with frontotemporal contusion or basal ganglia intracranial hemorrhage
- Need emergency intracranial hematoma evacuating operation
- Patient's agents are informed and consent the research
Who cannot join
- With TBI, stroke, ICH or intracranial tumor history
- Death within 24 hours
- Immunosuppression state
- Severe organ dysfunction
- Complicated infective disease
- Pregnant
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
Brain Injury Center, Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, Shanghai Municipality
Junfeng Feng, +8613611860825
About this study
The goal of this experimental observation study is to figure out differently expressed biomarkers in lesion tissues in traumatic brain injury or hypertension intracranial hemorrhage patients. The main questions it aims to answer is:
- Which RNA, protein and metabolites are differently expressed in lesion tissues?
- What molecular mechanism is participated in TBI or ICH? Participants will be treated by emergency operation, and their lesion tissues will be collected during the operation.
- Being tested
- Type of disease
- Keywords
- Traumatic brain injury, Hypertensive intracranial hemorrhage, Multiomic analysis, Biomarker, Molecular mechanism
- Medical subject headings
- Intracranial Hemorrhage, Hypertensive, Brain Injuries, Traumatic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Type of diseaseOther
Different types of pathogen: brain injury by trauma or intracranial hemorrhage due to hypertension.
| Study group | Role | What they receive |
|---|---|---|
| TBI | Patients with traumatic brain injury. Receives: Other: Type of disease | |
| ICH | Patients with hypertensive intracranial hemorrhage. Receives: Other: Type of disease |
What is being measured
The primary outcome is the main question the study is designed to answer.
RNA biomarkers in TBI or ICH patients' lesion tissues assessed by transcriptome bioinformatic analysis
Patients' lesion tissue will be collected during hematoma evacuation. Then these tissues will be immediately prepared to be detected through transcriptome sequencing. The results of transcriptome sequencing will be further analyzed by bioinformatic analysis to reveal different RNA expressions in lesion tissues of severe TBI and ICH patients as the potential biomarkers.
Measured: Immediately after collecting tissues
Protein biomarkers in TBI or ICH patients' lesion tissues assessed by proteomic bioinformatic analysis
Patients' lesion tissue will be collected during hematoma evacuation. Then these tissues will be immediately prepared to be detected through proteomics mass spectrometry. The results of proteomic will be further analyzed by bioinformatic analysis to reveal different protein expressions in lesion tissues of severe TBI and ICH patients as the potential biomarkers.
Measured: Immediately after collecting tissues
Metabolite biomarkers in TBI or ICH patients' lesion tissues assessed by metabolomic bioinformatic analysis
Patients' lesion tissue will be collected during hematoma evacuation. Then these tissues will be immediately prepared to be detected through metabolomic mass spectrometry. The results of metabolomic will be further analyzed by bioinformatic analysis to reveal different metabolite expressions in lesion tissues of severe TBI and ICH patients as the potential biomarkers.
Measured: Immediately after collecting tissues
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Mar 2023
- Study start1 Apr 2023
- Primary completion31 Mar 2024 (estimated)
- Study completion31 Dec 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Brain Injury Traumatic SevereStudies of the same condition, open and under way.
- More trials run by RenJi HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 10 participants (estimated)
Sponsor and investigators
- Lead sponsor
- RenJi Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Junfeng Feng, RenJi Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05778110
- Sponsor's protocol ID
- LY2023-017-B
- Acronym
- MOSS-THINK
- Status last verified
- May 2023
- First submitted
- 5 Feb 2023
- Last updated
- 3 May 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 May 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multiomic Analysis of Traumatic Brain Injury and Hypertension Intracranial Hemorrhage Lesion Tissue
- ClinicalTrials.gov ID
- NCT05778110
- Acronym / sponsor ID
- MOSS-THINK / LY2023-017-B
- Keywords
- Traumatic brain injury, Hypertensive intracranial hemorrhage, Multiomic analysis, Biomarker, Molecular mechanism
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 10 participants (estimated)
- Lead sponsor
- RenJi HospitalUniversity, hospital or other
- Study start
- 1 Apr 2023 (actual)
- Primary completion
- 31 Mar 2024 (estimated)
- Study completion
- 31 Dec 2024 (estimated)
- First posted
- 21 Mar 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this experimental observation study is to figure out differently expressed biomarkers in lesion tissues in traumatic brain injury or hypertension intracranial hemorrhage patients. The main questions it aims to answer is:
- Which RNA, protein and metabolites are differently expressed in lesion tissues?
- What molecular mechanism is participated in TBI or ICH? Participants will be treated by emergency operation, and their lesion tissues will be collected during the operation.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| TBI | – | Other: Type of diseasePatients with traumatic brain injury. |
| ICH | – | Other: Type of diseasePatients with hypertensive intracranial hemorrhage. |
Who may qualify
- Ages
- 16 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients with severe traumatic brain injury or hypertensive intracranial hemorrhage.
Key inclusion criteria (6 listed)
- Age >18 and <65
- Within 12 hours after brain injury
- GCS ≥3 and ≤8
- Closed brain injury with frontotemporal contusion or basal ganglia intracranial hemorrhage
- Need emergency intracranial hematoma evacuating operation
Key exclusion criteria (6 listed)
- With TBI, stroke, ICH or intracranial tumor history
- Death within 24 hours
- Immunosuppression state
- Severe organ dysfunction
- Complicated infective disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Type of diseaseDifferent types of pathogen: brain injury by trauma or intracranial hemorrhage due to hypertension. | Other | ICH, TBI |
Primary outcome
RNA biomarkers in TBI or ICH patients' lesion tissues assessed by transcriptome bioinformatic analysis
Time frame: Immediately after collecting tissues
Patients' lesion tissue will be collected during hematoma evacuation. Then these tissues will be immediately prepared to be detected through transcriptome sequencing. The results of transcriptome sequencing will be further analyzed by bioinformatic analysis to reveal different RNA expressions in lesion tissues of severe TBI and ICH patients as the potential biomarkers.
Protein biomarkers in TBI or ICH patients' lesion tissues assessed by proteomic bioinformatic analysis
Time frame: Immediately after collecting tissues
Patients' lesion tissue will be collected during hematoma evacuation. Then these tissues will be immediately prepared to be detected through proteomics mass spectrometry. The results of proteomic will be further analyzed by bioinformatic analysis to reveal different protein expressions in lesion tissues of severe TBI and ICH patients as the potential biomarkers.
Metabolite biomarkers in TBI or ICH patients' lesion tissues assessed by metabolomic bioinformatic analysis
Time frame: Immediately after collecting tissues
Patients' lesion tissue will be collected during hematoma evacuation. Then these tissues will be immediately prepared to be detected through metabolomic mass spectrometry. The results of metabolomic will be further analyzed by bioinformatic analysis to reveal different metabolite expressions in lesion tissues of severe TBI and ICH patients as the potential biomarkers.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 May 2023.
- Individual participant dataSharing planned: No
Related trials for Brain Injury Traumatic Severe
Not yet recruitingPhase 2/3
Valproic AcId for Traumatic BRAin INjury Trial
Moderate Traumatic Brain Injury (TBI), Severe Traumatic Brain Injury
RecruitingObservational study
Cortical Spreading Depolarization After Severe Traumatic Brain Injury
Traumatic Brain Injury
RecruitingObservational study
Predict Severe Traumatic Brain Injury
Traumatic Brain Injury
Not yet recruitingObservational study
Blood NfL and Functional Outcomes After Moderate-to-Severe TBI
Traumatic Brain Injury
Not yet recruitingObservational study
The Systemic Nature of Severe Traumatic Brain Injury
Severe Traumatic Brain Injury
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Brain Injury Traumatic Severe and Intracranial Hemorrhage, Hypertensive, run by RenJi Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 3 May 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Zhenghui He, MD (+8613585916217, hezhenghui8@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
RNA biomarkers in TBI or ICH patients' lesion tissues assessed by transcriptome bioinformatic analysis (time frame: Immediately after collecting tissues). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 May 2023; AzTrials last refreshed its copy on 8 Nov 2026.